Re-Registration in Belarus: From Resolution 487 to Resolution 211

1. Key takeaways

Re-registration — in the Russian original, перерегистрация — is in Belarus an independent procedure standing alongside the amendment procedure; its concrete arrangements were established in 2022 by Resolution No. 487, but that resolution lapsed with the old system on 2026-05-01. Handling re-registration today therefore means returning to the new framework of Resolution No. 211, not reusing the operational details of No. 487. Three points anchor the current position. First, the procedure itself survives: the title of Resolution No. 211 expressly retains the words re-registration, confirming that re-registration continues to exist as a distinct procedure under the new framework — only its textual carrier has changed. Second, the operational detail of No. 487 — its conditions, timing and material requirements — is no longer citable, because the resolution’s validity was expressly limited to 2026-05-01 and it was terminated by No. 211. Third, on the validity period of registration certificates, public sources offer two conflicting accounts, and neither can be verified against official text; both must be treated as pending verification and must not drive scheduling decisions.

2. Legal basis

3. Expert insights

Insight 1: The procedure name re-registration is retained in the title of the new resolution. The title of Resolution No. 211 reads, in full, on state registration (re-registration) of medical devices — the parenthetical is deliberate. It signals that re-registration survives as an independent procedure in the new framework, even though its earlier textual carrier, Resolution No. 1269 and its amendment No. 487, has been terminated. Companies should not conclude from the lapse of the old resolutions that re-registration has been abolished; what changed is the governing text, not the existence of the procedure. The correct reading is that everything operational about re-registration — when it must be initiated, what documents it requires, what it confirms — is now answered from No. 211 and from the current requirements of the organising body, and that any internal compliance calendar built on No. 487 needs to be rebuilt against the new framework.

Insight 2: The specific operational details of No. 487 can no longer be cited. The official record for No. 487 expressly marks its validity as limited to 2026-05-01, with No. 211 as the terminating instrument. GRZAN has not been able to obtain the article text of No. 487 on the conditions and timing of re-registration; accordingly, this series does not describe its specific thresholds and does not treat it as a current basis. This restraint has practical weight: intermediate articles circulating in the market still paraphrase No. 487-era requirements, and a company that copies them into an internal procedure imports obsolete rules into current filings. The safe position is procedural, not historical — for any re-registration question, ask what the current framework requires, in writing, and document the answer — rather than reconstructing the old regime from secondary sources and hoping the practice has survived unchanged.

Insight 3: On the validity period of registration certificates, public sources present two conflicting accounts. One account holds that the national registration certificate is indefinite — issued without an expiry date. The other holds that the first registration is valid for 5 years, becoming indefinite after re-registration — and this second account appears in public sources in both a medicinal-products context and a device context, creating a real risk of cross-domain contamination. GRZAN has not located an explicit provision on the validity period of device registration certificates in the official texts; therefore both accounts are treated as pending verification and are not written into conclusions. The operational rule that follows is strict: no company schedule should be built on either account until the actual status of its own certificates is confirmed in writing by the local representative or the organising body.

Insight 4: Re-registration timing must be reconfirmed under the new framework. For certificates issued under the old framework, the applicable rules for subsequent re-registration, the point at which it must be initiated and the materials it requires are all questions that the new framework answers — or will answer through current practice — differently from No. 487. Companies holding legacy certificates should not extrapolate from the old regime; they should map each held certificate, determine under Resolution No. 211 what its onward path is and when action is due, and confirm the outcome in writing with the local representative. Where the new framework has not yet generated settled practice for a given certificate type, that gap itself should be recorded as a risk item, with a planned confirmation date, rather than filled with assumptions borrowed from the lapsed rules.

4. Practical recommendations

1. Do not cite Resolution No. 487 as a current basis. From 2026-05-01, the basis for re-registration is Resolution No. 211; purge No. 487 references from internal procedures and templates.
2. Run a fitness check on legacy certificates. List every Belarusian registration certificate the company holds and confirm, one by one, the onward path and timing for each under the new framework.
3. Confirm validity-period status in writing. Do not schedule around intermediary accounts of 5 years or indefinite validity; obtain written confirmation of the actual status of the company’s certificates from the local representative or the organising body.
4. Manage re-registration separately from amendments. List the two procedures as separate items in the compliance calendar so they are never confused or routed through one another.

5. Verification checklist

• □ Citations of Resolution No. 487 discontinued; re-registration based on Resolution No. 211
• □ Fitness check completed for all legacy registration certificates
• □ Certificate validity-period status confirmed in writing (not from intermediary accounts)
• □ Compliance calendar lists re-registration and amendments as separate items
• □ Recorded that article numbers of No. 487 were not obtained — no invented citations

Regulatory information verified as of 2026-10-30.

On the Eurasian Economic Union market, GRZAN’s core capabilities concentrate on three points. First, distinguishing the applicable conditions and remaining time windows of the two pathways — Union-wide registration versus national registration in each member state: the national registration procedure for medical devices in Belarus has been switched wholesale by Council of Ministers Resolution No. 211 of 2026-04-28 (state register No. 6-1/55925, effective 2026-05-01), which compressed the total time limit for preliminary technical works to 90 calendar days, closed the list of such works and prohibited the organising body from expanding it, while the window for filing applications under the national procedure treats 2027-12-31 as the critical cut-off — pathway selection must therefore be decided in step with the time window. Second, authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Belarus, undertaking registration filings, responses to technical queries, registration dossier amendments and post-market reporting obligations, and has synchronised its coordination mechanisms after Council of Ministers Resolution No. 378 of 2026-07-27 (effective 2026-07-30) transferred adverse-event functions to the state organisation for pharmaceutical supervision. Third, quality system and testing support: assistance in establishing a quality management system conforming to ISO 13485, and in organising technical documentation according to the target pathway — the national pathway follows the annex to Ministry of Health Resolution No. 55, while the Union pathway follows EEC Council Decision No. 46.

For business inquiries: info@grzanglobal.com